IRB Study Number 19-1361
Status Recruiting
Phase Not Applicable
Locations Fairview Hospital, Cleveland Clinic Main Campus, Hillcrest Hospital, Weston Hospital
Institute Heart and Vascular Institute
Description
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
Patients will need to be randomized within 7 days after the qualifying atrial fibrillation (AF) event or by hospital discharge, whichever comes first. The protocol-specified duration of anticoagulation is 90 days. Patients, who are randomized to the control arm and develop recurrent AF after 30 days, may be crossed-over to an OAC.
Study follow-up visit will be performed at 30, 60, 90, and 180 days. An EKG will need to be preformed at the 90 day follow up visit.
Inclusion Criteria
1.Undergone isolated CABG
2. An episode of post operative Atrial fibrillation lasting 1 hour or multiple episodes of Atrial Fibrillation
Exclusion Criteria
1.No post operative atrial fibrillation
2. Concomitant surgery
3. Use of post operative dual anilatlete therapy (DAPT)
